Shanghai, China – May 4, 2026 – Shanghai Henlius Biotech, Inc. (2696.HK) today announced that its innovative anti-PD-L1 antibody–drug conjugate (ADC), HLX43, has been permitted by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) to conduct the HLX43-NSCLC302 study — an international, multicenter phase 2/3 clinical trial in patients with advanced squamous non-small cell lung cancer (sqNSCLC). The trial will be conducted across multiple countries, including China, the United States, and Japan. The phase 3 stage is expected to serve as the first pivotal registration study for HLX43 and represents a significant milestone for HLX43 in the field of NSCLC, poised to offer a new therapeutic option for refractory sqNSCLC patients who have progressed on prior standard therapies.

(Hong Kong, 28 April 2026) Fosun International Limited (HKEX stock code: 00656, “Fosun International”), together with its subsidiaries (“Fosun” or the “Group”), released the Environmental, Social and Governance (ESG) Report 2025 (the “ESG Report”). Facing the increasingly severe challenges of global climate change, Fosun released its fourth Climate Information Disclosures Report with reference to Part D (“New Climate Requirements”) of Appendix C2 “Environmental, Social and Governance Reporting Code” of the Main Board Listing Rules of the Hong Kong Stock Exchange, the framework of the Task Force on Climate-Related Financial Disclosures (TCFD) recommendations and the International Financial Reporting Standards S2 Climate-related Disclosures Requirements (“IFRS S2”).

For 2026, the World Health Organization (WHO) has designated the theme for this year’s World Malaria Day as “Driven to End Malaria: Now We Can. Now We Must”, calling on the global community to seize the moment and accelerate efforts, in the fight for a malaria-free future.

On the morning of 31 March, Guo Guangchang, Chairman of Fosun International, stated at Fosun International’s 2025 annual results presentation that the RMB23.4 billion impairment provision was a “prudent accounting measure, not a reflection of operational issues”. He described the impairment as “repairing the roof on a sunny day” and said that the management is confident in Fosun’s future development.

On 31 March, Fosun International held its 2025 annual results presentation in Shanghai. Guo Guangchang, Chairman of Fosun International; Wang Qunbin, Co-Chairman of Fosun International; Chen Qiyu, Co-CEO of Fosun International; Xu Xiaoliang, Co-CEO of Fosun International; Gong Ping, CFO of Fosun International, as well as a number of institutional investors and analysts attended the event.

On 30 March, Fosun International (00656.HK) announced its results for the 12 months ended 31 December 2025. In 2025, Fosun’s fundamentals remained solid, core industries such as pharmaceuticals and healthcare and insurance and finance demonstrated a good development trend, and the twin drivers of innovation and globalization delivered strong momentum.

Today, I would like to have an open and honest conversation with our shareholders, reflecting on Fosun’s journey in 2025, sharing our thoughts, and outlining where we are heading next.

(26 March 2026) The world’s leading index company MSCI recently released its latest annual Environmental, Social and Governance (“ESG”) ratings. The results, announced in March 2026, are based on MSCI’s latest rating model (version 5.0). Thanks to its outstanding performance across all ESG aspects, Fosun International Limited (HKEX stock code: 00656, hereinafter referred to as “Fosun International”, “Fosun”, or the “Group”) saw its rating rise from AA to AAA. This marks Fosun International’s first time achieving the highest MSCI ESG rating since first earning an AA rating in 2021, following five years of sustained efforts, demonstrating Fosun’s achievements and global leadership in sustainability.

SHANGHAI, March 13, 2026 -- Fosun International Limited ("Fosun International", stock code: 00656.HK) and HSBC Bank (China) Company Limited ("HSBC China") renewed a strategic cooperation agreement (the "Agreement") today to provide strong support for Fosun International and its subsidiaries ("Fosun") in further enhancing global operation and investment capabilities, advancing future growth strategies, and strengthening financial resources.